Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group

ObjectiveThis prospective real-world study, conducted by the Greek Research Alliance for the Study of Headache and Pain (GRASP), aimed to evaluate the efficacy, tolerability and safety of subcutaneous galcanezumab 240 mg in reducing the frequency and clinical burden of CH attacks at week 4.MethodsTh...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Michail Vikelis, Andreas A. Argyriou, Maria Chondrogianni, Aikaterini Foska, Dimitrios Rikos, Christos Tsironis, Panagiotis Soldatos, Maria Koutsokera, Emmanouil V. Dermitzakis
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-01-01
Serie:	Frontiers in Neurology
Soggetti:	chronic cluster headache effectiveness episodic cluster headache galcanezumab prevention safety
Accesso online:	https://www.frontiersin.org/articles/10.3389/fneur.2025.1748498/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!